Assembly Bio Interim Phase 1b Results from Chronic Hepatitis B Trial

 – ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –

– In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment –

– Enrollment in final cohort of 400 mg ongoing with data anticipated in 1H 2025 –

https://www.globenewswire.com/news-release/2024/12/26/3001938/16259/en/Assembly-Biosciences-Reports-Interim-Phase-1b-Results-from-Clinical-Trial-Evaluating-Next-Generation-Capsid-Assembly-Modulator-Candidate-ABI-4334-in-Chronic-Hepatitis-B.html